Login to Your Account



Financings Roundup

ThromboGenics Extends Runway with $103.2M Raise

By Marie Powers
Staff Writer

Friday, March 30, 2012
Ten days after inking a potential $494 million deal with eye care specialist Alcon Inc. for the ex-U.S. rights to vitreous macular adhesion (VMA) candidate ocriplasmin, ThromboGenics NV raised €77.8 million (US$103.2 million) in a private placement of 3,244,677 new shares with domestic and international investors.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription